Index

Note: Page numbers of article titles are in **boldface** type.

A

ACLF. See Acute-on-chronic liver failure (ACLF)

Acute kidney injury (AKI)
   in ACLF patients, 967

Acute liver failure (ALF), 957–964
   causes of, 958–959
   defined, 957–958
   incidence of, 958–959
   management of, 959–964
      bioartificial liver support systems in
         clinical efficacy of, 948–949
         cause-specific, 959–960
         complications-related, 960–962
         liver transplantation in, 962–964
         non-cause-specific, 960

Acute-on-chronic liver failure (ACLF)
   described, 964
   management of
      artificial liver support systems in
         clinical efficacy of, 949–953
         ICU, 964–970
         pathophysiology of, 964
         prognosis of
            initial assessment of, 964–970

Acute variceal bleeding (AVB), **793–808**
   described, 793–794
   management of
      esophageal stents in, 800–803
      general, 795
      hemostatic therapies in, 795–800
         EBL, 796–800
         endoscopic therapy, 796
         splanchnic vasoconstrictors, 795–796
      TIPS in, 855
      natural history/diagnosis of, 794–795
      refractory
         TIPS for, 855–857

AKI. See Acute kidney injury (AKI)

Alcoholic hepatitis
   HVPG measurement in, 785

ALF. See Acute liver failure (ALF)
Ascites
   refractory
      TIPS for, 857
AVB. See Acute variceal bleeding (AVB)

B
Balloon-occluded retrograde transvenous obliteration (BRTO) procedure
   in gastric varices management, 819, 833–847
      outcomes in American institutions, 844–846
      outcomes in Asian institutions, 837–844
      TIPS with
         outcomes of, 846–847
   Balloon tamponade
      in gastric varices management, 814
Bile duct stones
   cholangioscopy for
      outcomes of, 932–934
Biliary anastomotic strictures
   after liver transplantation
      cholangioscopy for, 921
      diagnostic approach to, 915–916
      ERCP for, 913–926. See also Endoscopic retrograde cholangiopancreatography
      (ERCP), for biliary anastomotic strictures after liver transplantation
         recurrence of, 920
         risk factors for, 915
         treatment of, 916–920
Biliary malignancies
   suspected
      cholangioscopy for
         outcomes of, 934–937
Biliary strictures
   anastomotic. See Biliary anastomotic strictures
   LDLT and, 920–921
   types of, 914–915
Bleeding
   acute variceal, 793–808. See also Acute variceal bleeding (AVB)
   gastrointestinal
      in ACLF patients, 969–970
      refractory
         gastric varices and portal hypertensive gastropathy and, 857
         variceal. See Variceal bleeding
   BRTO procedure. See Balloon-occluded retrograde transvenous obliteration (BRTO)
   procedure
Budd-Chiari syndrome
   TIPS for, 859

C
Cancer(s). See also Carcinoma(s)
   liver
radioembolization for, 882–883
TACE for, **877–890. See also** Transarterial chemoembolization (TACE), for liver cancer
Carcinoma(s). See also Cancer(s)
hepatocellular. See Hepatocellular carcinoma (HCC)
Chemoembolization
transarterial
for liver cancer. See also Transarterial chemoembolization (TACE)
Cholangiocarcinoma
benign stenosis vs.
in PSC patients, 906–907
described, 891
ERCP for, **891–897. See also** Endoscopic retrograde cholangiopancreatography (ERCP)
Cholangioscopy
in liver disease, **927–944**
approach to, 929–930
for bile duct stones
outcomes of, 932–934
for biliary anastomotic strictures after liver transplantation, 921
clinical implications of, 938
complications/management of, 938
current controversies/future considerations in, 938–939
follow-up care, 938
indications/contraindications to, 928
introduction, 927–928
outcomes of, 931–937
postprocedure care, 938
preparation for, 928–929
for PSC, 907
outcomes of, 937
reporting of, 938
for suspected biliary malignancies
outcomes of, 934–937
technique for, 930–931
Cholangitis
primary sclerosing
ERCP for, **899–911. See also** Endoscopic retrograde cholangiopancreatography (ERCP), for PSC; Primary sclerosing cholangitis (PSC)
Chronic liver disease (CLD)
described, 768
Cirrhosis
prognosis of
HVPG measurement in, 784–785
severity of
HVPG measurement in, 784–785
CLD. See Chronic liver disease (CLD)
Conventional TACE (cTACE)
for liver cancer
technique/procedure for, 879–881
D
Drug-eluting bead TACE
for liver cancer
  technique/procedure for, 882

E
EBL. See Endoscopic band ligation (EBL)
Endoscopic band ligation (EBL)
in AVB management, 796–800
  in gastric varices management, 816
Endoscopic retrograde cholangiopancreatography (ERCP)
  for biliary anastomotic strictures after liver transplantation, 913–926
    complications of, 921
    dilation and plastic stent placement, 917
    introduction, 913–914
    limitations of, 918–920
    self-expandable metal stents, 917–918
  for cholangiocarcinoma, 891–897
    complications/management of, 894–895
    current controversies/future considerations in, 896
    indications/contraindications to, 891–892
    outcomes of, 895–896
    postoperative care, 895
    technique/procedure for, 892–894
    introduction, 891
  for PSC, 899–911. See also Primary sclerosing cholangitis (PSC)
    complications of, 905–907
    introduction, 899–900
Endoscopic sphincterotomy
  for PSC, 902
Endoscopic stent placement
  for PSC, 903–904
Endoscopic stricture dilation
  for PSC, 902–903
Endoscopic therapies
  in AVB management, 796
    combined
      in gastric varices management, 818
      in gastric varices management, 814
      in gastric varices prevention, 820
Endoscopic ultrasound (EUS)–guided therapy
  in gastric varices management, 818–819
Endovascular procedures
  in gastric varices management, 829–851. See also specific methods and Gastric varices, management of, endovascular
ERCP. See Endoscopic retrograde cholangiopancreatography (ERCP)
Esophageal stents
  in AVB management, 800–803
EUS. See Endoscopic ultrasound (EUS)
Gastric varices

acute
  management of, 813
anatomy related to, 830–833
vascular, 811–812
classification of, 810, 830–833
hemodynamic features of, 811–812
introduction, 809–810
management of, 809–851
  balloon tamponade in, 814
  band ligation in, 816
  BRTO procedure in, 819, 833–847
  endoscopic therapies in, 814
    combined, 818
endovascular, 829–851
  BRTO procedure, 833–837
    outcomes in American institutions, 844–846
    outcomes in Asian institutions, 837–844
  introduction, 829–830
  TIPS only in
    outcomes of, 846
  EUS–guided treatment in, 818–819
  medical, 813–814
  obturation in, 815–816
  primary prophylaxis in, 812–813
  radiologic interventions in, 819
  risk factors associated with, 813
  sclerotherapy in, 814–815
  secondary prophylaxis in, 820–821
  thrombin in, 817–818
  TIPS in, 819
  refractory bleeding from
    TIPS for, 857
  terminology related to, 830–833
Gastroesophageal varices. See also Gastric varices
  introduction, 809–810
Gastrointestinal bleeding
  in ACLF patients, 969–970
Gastropathy
  portal hypertensive
    refractory bleeding from
      TIPS for, 857

H

HCC. See Hepatocellular carcinoma (HCC)
Hemodynamic instability
  in ACLF patients
    management of, 965–967
Hemostatic therapies
  in AVB management, 795–800. See also Acute variceal bleeding (AVB), management of, hemostatic therapies in

Hepatic venoocclusive disease
  TIPS for, 859

Hepatic venous pressure gradient (HVPG) measurement, 780–782
  applications of, 783–788
  alcoholic hepatitis, 785
  assessment of new therapeutic agents, 788
  assessment of response to pharmacologic therapy to decrease portal pressure, 786–788
  cirrhosis prognosis, 784–785
  cirrhosis severity, 784–785
  hepatocellular carcinoma, 786
  liver transplantation, 785–786
  portal hypertension classification, 784
  portal hypertension diagnosis, 783–784
  viral hepatitis, 785

Hepatitis
  alcoholic
    HVPG measurement in, 785
  viral
    HVPG measurement in, 785

Hepatocellular carcinoma (HCC)
  HVPG measurement in, 786
  introduction, 877–879

Hepatopulmonary syndrome (HPS)
  TIPS for, 858–859

Hepatorenal syndrome (HRS)
  TIPS for, 859

HPS. See Hepatopulmonary syndrome (HPS)

HRS. See Hepatorenal syndrome (HRS)

HVPG. See Hepatic venous pressure gradient (HVPG)

Hydrothorax
  refractory hepatic
    TIPS for, 858

Hypertension
  portal. See Portal hypertension

I

ICU. See Intensive care unit (ICU)

Infection(s)
  in ACLF patients, 964

Intensive care unit (ICU)
  liver failure patients in
    management of, 957–978. See also Liver failure, ICU management of patients with
  Interventional radiologic approach
    in gastric varices prevention, 820
LDLT. See Living donor liver transplantation (LDLT)

Liver biopsy
- transjugular, 767–778. See also Transjugular liver biopsy (TJLB)

Liver cancer
- radioembolization for, 882–883
- TACE for, 877–890. See also Transarterial chemoembolization (TACE), for liver cancer

Liver disease
- cholangioscopy in, 927–944. See also Cholangioscopy, in liver disease

Liver failure
- acute. See Acute liver failure (ALF)
- acute-on-chronic. See Acute-on-chronic liver failure (ACLF)
- ICU management of patients with, 957–978
  - ACL patients, 957–964. See also Acute liver failure (ALF)
  - ACLF patients, 964–970
- liver support systems in, 945–956. See also Liver support systems

Liver support systems
- bioartificial
  - in ALF, 948–949
- extracorporeal
  - technical characteristics of, 946
- in liver failure, 945–956
  - artificial vs. bioartificial systems analysis
    - clinical studies, 953
  - clinical efficacy of, 948–953
    - in ACLF, 949–953
    - in ALF, 949
  - bioartificial liver support systems in ALF, 948–949
- future considerations, 953–954
- ideal
  - requirements for, 953–954
  - in improving liver regeneration, 948
  - in improving portal and systemic hemodynamics, 947–948
  - rationale for, 946–948
  - in toxins elimination, 946–947
  - necessity of, 945–946

Liver transplantation
- for ALF, 962–964
- biliary anastomotic strictures after. See also Biliary anastomotic strictures, after liver transplantation
  - ERCP for, 913–926. See also Biliary anastomotic strictures; Endoscopic retrograde cholangiopancreatography (ERCP), for biliary anastomotic strictures after liver transplantation
- HVPG measurement and, 785–786
- living donor
  - biliary strictures and, 920–921

Living donor liver transplantation (LDLT)
- biliary strictures and, 920–921
Malignancy(ies)  
biliary  
suspected  
cholangioscopy for, 934–937  

Medical therapies  
in gastric varices prevention, 820  

Neurologic complications  
in ACLF patients, 967–969  

Obturation  
in gastric varices management, 815–816  

Partial splenic embolization (PSE)  
in gastric varices prevention, 820  

Portal hypertension  
classification of  
HVPG measurement in, 784  
described, 779–780  
diagnosis of  
HVPG measurement in, 783–784  

Portal hypertensive gastropathy  
refractory bleeding from  
TIPS for, 857  

Portal pressure  
decrease in  
HVPG measurement in assessment of response to pharmacologic therapy for,  
786–788  
introduction, 779–780  
measurement of, 779–792  
HVPG–related, 780–782  

Primary sclerosing cholangitis (PSC)  
cholangioscopy for  
outcomes of, 937  
cholangioscopy in  
role of, 907  
described, 899–900  
diagnosis of, 900  
dominant stricture in, 900–901  
management of  
endoscopic, 902–904  
medical, 901  
nonendoscopic, 901–902  
percutaneous, 901  
surgical, 902
endoscopic management of
efficacy of, 904
ERCP for, 899–911. See also Endoscopic retrograde cholangiopancreatography
(ERCP), for PSC
PSC. See Primary sclerosing cholangitis (PSC)
PSE. See Partial splenic embolization (PSE)
Pulmonary complications
in ACLF patients, 970

R
Radioembolization
for liver cancer, 882–883
Radiologic procedures
in gastric varices management, 819
Refractory acute variceal bleeding
TIPS for, 855–857
Refractory ascites
TIPS for, 857
Refractory bleeding
 gastric varices and portal hypertensive gastropathy and
TIPS for, 857
Refractory hepatic hydrothorax
TIPS for, 858

S
Sclerotherapy
in gastric varices management, 814–815
Septic shock
in ACLF patients
management of, 965–967
Sphincterotomy
endoscopic
for PSC, 902
Splanchnic vasoconstrictors
in AVB management, 795–796
Stent(s)
esophageal
in AVB management, 800–803
Suspected biliary malignancies
cholangioscopy for
outcomes of, 934–937

T
TACE. See Transarterial chemoembolization (TACE)
Thrombin
 in gastric varices management, 817–818
TIPS. See Transjugular intrahepatic portosystemic shunts (TIPS)
TJLB. See Transjugular liver biopsy (TJLB)
Index

Toxin(s)
liver failure–related
 elimination of
  liver support systems in, 946–947
Transarterial chemoembolization (TACE)
for liver cancer, 877–890
  clinical implications of, 884–885
  complications/management of, 883
cTACE
  technique/procedure for, 879–881
  current controversies/future considerations in, 886–888
  drug-eluting bead–type
    technique/procedure for, 882
  follow-up care, 884–885
  indications/contraindications for, 879
  introduction, 877–879
  outcomes of, 885–886
  postprocedure care, 883–884
  reporting related to, 884–885
  technique/procedure for, 879–883
Transjugular intrahepatic portosystemic shunts (TIPS), 853–876
  advanced/alternative techniques for, 864
  complications of, 864–867
  conventional technique for, 860–864
  evaluation prior to, 859–860
  follow-up care, 867
  future considerations in, 867
  in gastric varices management, 819
    with BRTO procedure
      outcomes of, 846–847
    outcomes of, 846
  indications for, 854–859
    AVB, 855
      refractory, 855–857
    Budd-Chiari syndrome, 859
    hepatic venoocclusive disease, 859
    HPS, 858–859
    HRS, 859
    refractory ascites, 857
    refractory bleeding from gastric varices and portal hypertensive gastropathy, 857
    refractory hepatic hydrothorax, 858
    variceal hemorrhage prevention, 854–855
  introduction, 853–854
  maintenance care, 867
  patient selection for, 859–860
Transjugular liver biopsy (TJLB), 767–778
  complications/management of, 774
  current controversies/future considerations in, 776
  indications/contraindications to, 768
  sample quality and clinical implications in, 774–776
  technique/procedure for, 768–774
Transplantation(s)
  liver. See Liver transplantation

V

Variceal bleeding
  acute
  refractory
    TIPS for, 855–857
    TIPS for, 855
  prevention of
    TIPS in, 854–855

Varices
  gastric. See Gastric varices

Vasoconstrictor(s)
  splanchnic
    in AVB management, 795–796

Venoocclusive disease
  hepatic
    TIPS for, 859

Viral hepatitis
  HVPG measurement in, 785